| HOME >> BIOLOGY >> TECHNOLOGY |
PASADENA, Calif., Oct. 22 /PRNewswire/ -- Maven Biotechnologies, LLC, an early stage biotechnology company developing a label-free multiplexing immunodiagnostic analysis system, today announced that the company will deliver a presentation at the BIOCOM Investor Conference in San Diego, California. Jeffrey C. Travis, Ph.D., Maven's President and COO, will present on Thursday, November 1, 2007 at 3:30 PM.
About Maven Biotechnologies
Maven Biotechnologies, LLC has developed LFIRE(TM) (Label-Free Internal
Reflection Ellipsometry) which is a complete diagnostics analysis system
(instruments and disposables) that provides a next generation replacement
measurement technology with significant cost benefits to the healthcare
sector and technology improvements for the combined $15 B w/w
immunodiagnostic markets. It offers the potential advantages of 50-75%
reduced costs to both the diagnostics manufacturers and the clinical or
pharma lab user. In addition, its breakthrough new way to measure
immunodiagnostic tests more rapidly will positively impact point-of-care
(POC) tests for emergency room screening (e.g. cardiac markers, drugs of
abuse, etc.), at patient bedside, and in the O.R. Finally, it uniquely
permits single to high density label-free multiplexing -- that is, when one
to large numbers of tests per patient can be run at one time (e.g. tumor
markers, autoimmune panels, etc.), greatly reducing costs for the patients,
healthcare provider and importantly, the medical insurance industry.
LFIRE(TM) is an enabling technology for more cost effective patient
profiling of multiple tests for diagnosis, staging of disease and choice of
targeted drug therapy, all key elements required for the medical industry's
personalized medicine initiative. Most significantly, the market
infrastructure for this technology already exists in the worldwide
diagnostics and pharma industries and market penetration for this improved
next generation, markedly cost effective, repl
'/>"/>
| SOURCE Maven Biotechnologies, LLC Copyright©2007 PR Newswire. All rights reserved |